Trial Profile
A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Johnson & Johnson
- 16 Aug 2023 Status changed from active, no longer recruiting to completed.
- 23 Mar 2023 Planned primary completion date changed from 28 Feb 2022 to 15 Apr 2023.
- 04 May 2022 Status changed from recruiting to active, no longer recruiting.